WO2024141076A1 - Promédicaments pour analogues d'hormones thyroïdiennes et leur procédé de fabrication et d'utilisation - Google Patents

Promédicaments pour analogues d'hormones thyroïdiennes et leur procédé de fabrication et d'utilisation Download PDF

Info

Publication number
WO2024141076A1
WO2024141076A1 PCT/CN2023/143537 CN2023143537W WO2024141076A1 WO 2024141076 A1 WO2024141076 A1 WO 2024141076A1 CN 2023143537 W CN2023143537 W CN 2023143537W WO 2024141076 A1 WO2024141076 A1 WO 2024141076A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
compound
unsaturated
substituents
Prior art date
Application number
PCT/CN2023/143537
Other languages
English (en)
Inventor
Jinzi Jason Wu
Original Assignee
Gannex Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gannex Pharma Co., Ltd. filed Critical Gannex Pharma Co., Ltd.
Publication of WO2024141076A1 publication Critical patent/WO2024141076A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Definitions

  • One aspect of the present application relates to a compound of Formula I:
  • R 4 is -COR 5 , -COOR 5 , wherein R 5 is C 8-30 unsaturated or saturated alkyl or aliphatic group; wherein each of R 6 and R 7 is independently H, or C 1-3 alkyl; wherein the C 1-3 alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of -OH, halo and Ar; wherein Ar is aryl or heteroaryl; and the Ar is optionally substituted with one or more one or more substituents each independently selected from the group consisting of, halo, C 1-3 alkyl, -O-C 1-3 alkyl, haloalkyl and haloalkoxy; and wherein R 8 is C 1-30 unsaturated or saturated alkyl or aliphatic group.
  • Unsaturated alkyl is a monovalent or divalent linear or branched unsaturated hydrocarbon radical.
  • the term “unsaturated” means more hydrogen atoms may be added to the hydrocarbon to make it saturated (i.e. consisting all single bonds) .
  • Examples of “unsaturated alkyl” groups include alkenes and alkynes.
  • Aliphatic refers to a non-aromatic hydrocarbon-based moiety.
  • Aliphatic compounds can be acyclic (e.g., linear or branched) or cyclic moieties (e.g., cycloalkyl) and can be saturated or unsaturated (e.g., alkyl, alkenyl, and alkynyl) .
  • Aliphatic compounds may comprise a mostly carbon main chain (e.g., 1 to about 30 carbons) and comprise heteroatoms and/or substituents (see below) .
  • alkyl, as employed herein, includes saturated or unsaturated, straight or branched chain hydrocarbons containing 1 to about 30 carbons in the normal/main chain.
  • the hydrocarbon chain of the alkyl groups may be interrupted with one or more heteroatom (e.g., oxygen, nitrogen, phosphorus or sulfur) .
  • An alkyl (or aliphatic) may, optionally, be substituted (e.g. with fewer than about 8, fewer than about 6, or 1 to about 4 substituents) .
  • the term “lower alkyl” or “lower aliphatic” refers to an alkyl or aliphatic, respectively, which contains 1 to 3 carbons in the hydrocarbon chain.
  • Aliphatic and alkyl groups having at least about 5 carbons in the main chain are generally hydrophobic, absent extensive
  • Halogen or “Halo” refers to fluoro (-F) , chloro (-Cl) , bromo (-Br) and iodo (-I) .
  • Haloalkyl is an alkyl as defined herein, where one or more hydrogen atoms of the alkyl are independently replaced by a halogen, which may be the same or different, such that the alkyl is divalent.
  • the alkyl group and the halogen can be any of those described above.
  • the haloalkyl defines the number of carbon atoms in the alkyl portion, e.g., C 1-4 haloalkyl includes CF 3 , CH 2 F, CHF 2 , CH 2 CF 3 , CH 2 CH 2 CF 3 , CCl 2 CH 2 CH 2 CH 3 , and C (CH 3 ) 2 (CF 2 H) .
  • Haloalkyl groups can be unsubstituted or substituted.
  • Alkylaryl refers to an alkyl as defined herein, where one or more hydrogen atoms of the alkyl are independently replaced by an aryl group, which may be the same or different.
  • the alkyl group and the aryl group can be any of those described above, such that the alkyl is divalent.
  • an alkylaryl group has 7 to 24 carbon atoms, 7 to 16 carbon atoms, 7 to 13 carbon atoms, or 7 to 11 carbon atoms.
  • An alkylaryl group defined by the number of carbon atoms refers to the total number of carbon atoms present in the constitutive alkyl and aryl groups combined.
  • 5-10 membered heteroaryl refers to a single aromatic ring that has at least one atom other than carbon in the ring, where the atom is selected from the group consisting of oxygen, nitrogen and sulfur; “5-10 membered heteroaryl” also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below.
  • “5-10 membered heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic.
  • a 5-10 membered heteroaryl (asingle aromatic ring or multiple condensed ring system) can have about 1-20 carbon atoms and about 1-6 heteroatoms within the 5-10 membered heteroaryl ring.
  • tetrazolyl has 1 carbon atom and 4 nitrogen heteroatoms within the ring.
  • the rings of the multiple condensed ring system can be connected to each other via fused bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another.
  • Substituted refers to where one or more hydrogen atoms of the group are independently replaced by one or more substituents (e.g., 1, 2, 3, or 4 or more) as indicated.
  • a “compound of the present application” includes compounds disclosed herein, for example a compound of the present application includes compounds of Formula I, including the compounds of the Examples. In some embodiments, a “compound of the present application” includes compounds of Formula I.
  • “Pharmaceutically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • Co-administration refers to administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents.
  • a unit dose of a compound of the present application is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents.
  • a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present application within seconds or minutes.
  • compositions or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
  • Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1, 4-dioates, hexyne-1, 6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, be
  • Examples of “pharmaceutically acceptable salts” of the compounds disclosed herein also include salts derived from an appropriate base, such as an alkali metal (for example, sodium, potassium) , an alkaline earth metal (for example, magnesium) , ammonium and N (C 1 -C 4 alkyl) 4 + . Also included are base addition salts, such as sodium or potassium salts.
  • n is the number of hydrogen atoms in the molecule.
  • the deuterium atom is a non-radioactive isotope of the hydrogen atom.
  • Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism” , Trends Pharmacol. Sci., 5 (12) : 524-527 (1984) .
  • Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
  • isotopes that can be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
  • isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
  • Substitution with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • PET Positron E
  • Optically active (+) and (-) , (R) -and (S) -, or (D) -and (L) -isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
  • Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC) .
  • HPLC high pressure liquid chromatography
  • Tautomer refers to a proton shift from one atom of a molecule to another atom of the same molecule. In some embodiments, the present application includes tautomers of said compounds.
  • Solvate refers to the result of the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
  • Prevention means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop.
  • Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
  • At risk individual refers to an individual who is at risk of developing a condition to be treated.
  • An individual “at risk” may or may not have detectable disease or condition, and may or may not have displayed detectable disease prior to the treatment of methods described herein.
  • At risk denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual having one or more of these risk factors has a higher probability of developing the disease or condition than an individual without these risk factor (s) .
  • One aspect of the present application relates to a compound of Formula I:
  • R 4 is -COR 5 , -COOR 5 , R 5 is C 8-30 unsaturated or saturated alkyl or aliphatic group; each of R 6 and R 7 is independently H, or C 1-3 alkyl; and C 1-3 alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of -OH, halo and Ar; Ar is aryl or heteroaryl; and Ar is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-3 alkyl, -O-C 1-3 alkyl, haloalkyl and haloalkoxy; R 8 is C 1-30 unsaturated or saturated alkyl or aliphatic group.
  • Another aspect of the present application relates to a compound of Formula III:
  • Another aspect of the present application relates to a compound of Formula IV:
  • R 4 is -COR 5 , -COOR 5 , R 5 is C 21-30 unsaturated or saturated alkyl or aliphatic group; each of R 6 and R 7 is independently H, or C 1-3 alkyl; and the C 1-3 alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of -OH, halo and Ar; the Ar is aryl or heteroaryl; and the Ar is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-3 alkyl, -O-C 1-3 alkyl, haloalkyl and haloalkoxy; and R 8 is C 1-30 unsaturated or saturated alkyl or aliphatic group.
  • the compound of the present application is selected from the group consisting of the following compounds:
  • the present application also relates to formula (I) compounds or the stereoisomer, pharmaceutically acceptable salt, deuterated compounds, hydrate or solvate thereof or the said pharmaceutical composition in the preparation for the treatment and/or prevention of obesity, hyperlipidemia, hypercholesterolemia, diabetes mellitus, nonalcoholic steatohepatitis (NASH) , hepatic steatosis, arteriosclerosis, cardiovascular disease, hypothyroidism, or thyroid cancer.
  • NASH nonalcoholic steatohepatitis
  • Typical embodiments of compounds in accordance with the present application may be synthesized using the general reaction schemes and/or examples described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Starting materials are typically obtained from commercial sources or synthesized using published methods for synthesizing compounds which are embodiments of the present application, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. Group labels (e.g., R1, R2) used in the reaction schemes herein are for illustrative purposes only and unless otherwise specified do not necessarily match by name or function the labels used elsewhere to describe compounds of Formula I or aspects or fragments thereof.
  • Group labels e.g., R1, R2
  • the compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc. ) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
  • Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T.W. Greene and G.M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente demande concerne un dérivé agoniste du sous-type β du récepteur de l'hormone thyroïdienne, son procédé de préparation et son utilisation, et plus particulièrement un dérivé MGL-3196, son procédé de préparation et son utilisation.
PCT/CN2023/143537 2022-12-29 2023-12-29 Promédicaments pour analogues d'hormones thyroïdiennes et leur procédé de fabrication et d'utilisation WO2024141076A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202211704527.3 2022-12-29
CN202211704527 2022-12-29
US202363479829P 2023-01-13 2023-01-13
US63/479,829 2023-01-13
US202363480565P 2023-01-19 2023-01-19
US63/480,565 2023-01-19
US202363484301P 2023-02-10 2023-02-10
US63/484,301 2023-02-10

Publications (1)

Publication Number Publication Date
WO2024141076A1 true WO2024141076A1 (fr) 2024-07-04

Family

ID=91716545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/143537 WO2024141076A1 (fr) 2022-12-29 2023-12-29 Promédicaments pour analogues d'hormones thyroïdiennes et leur procédé de fabrication et d'utilisation

Country Status (1)

Country Link
WO (1) WO2024141076A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009913A1 (fr) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne
WO2009037172A1 (fr) * 2007-09-20 2009-03-26 F. Hoffmann-La Roche Ag Promédicaments pour analogues de l'hormone thyroïdienne
CN110938094A (zh) * 2018-09-21 2020-03-31 四川海思科制药有限公司 一种甲状腺激素受体β亚型激动剂衍生物的制备方法和用途
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009913A1 (fr) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne
WO2009037172A1 (fr) * 2007-09-20 2009-03-26 F. Hoffmann-La Roche Ag Promédicaments pour analogues de l'hormone thyroïdienne
CN110938094A (zh) * 2018-09-21 2020-03-31 四川海思科制药有限公司 一种甲状腺激素受体β亚型激动剂衍生物的制备方法和用途
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
WO2021078274A1 (fr) * 2019-10-24 2021-04-29 苏州泽璟生物制药股份有限公司 Composé de pyridazinone ou de pyridazine et dérivé et composition pharmaceutique de celui-ci

Similar Documents

Publication Publication Date Title
CN101146529B (zh) 新颖噻吩衍生物作为鞘氨醇-1-磷酸酯-1受体激动剂
JP2023030076A (ja) Ｆｘｒアゴニストの固体形態
WO2016150255A1 (fr) Dérivé cyclique condensé, et procédé de préparation, intermédiaire, composition pharmaceutique et utilisation de celui-ci
CN105636953A (zh) 1,4-二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
BR112016029333B1 (pt) Processo para preparação de compostos de carbamoilpiridona policíclico
CN108033964B (zh) 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用
CN112409340B (zh) 卤素取代的苯醚类化合物及其用途
JP6884800B2 (ja) メマンチン化合物及びその調整並びにその使用
WO2023061406A1 (fr) Inhibiteur de parp contenant une structure tricyclique condensée, son procédé de préparation et son utilisation médicale
JP7561978B2 (ja) ベンザミド類化合物及びその使用
WO2021078274A1 (fr) Composé de pyridazinone ou de pyridazine et dérivé et composition pharmaceutique de celui-ci
US20070093505A1 (en) 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators
CN114057701A (zh) 一种氘代哒嗪酮类化合物及其用途
JPH0367071B2 (fr)
EP0343050B1 (fr) Dérivés de phényl-6 pipérazinyl-alkyl-3 1H,3H-pyrimidinedione-2,4, leur préparation et leur application en thérapeutique
CN109678815B (zh) N-苄基苯甲酰胺类衍生物及其制备方法与制药用途
WO2024141076A1 (fr) Promédicaments pour analogues d'hormones thyroïdiennes et leur procédé de fabrication et d'utilisation
CN112142746B (zh) 苯二氮卓类化合物及其制备方法和在医药上的作用
CN111517969B (zh) 地佐辛衍生物及其医药用途
JP2018522068A (ja) Ｉｄｈ２突然変異を標的とする抗腫瘍化合物及びその使用方法
US11760751B2 (en) Benzo 2-azaspiro[4.4]nonane compound and use thereof
US20240294561A1 (en) Prodrugs of Thyroid Hormone Analogs, Methods of Making and Methods of Using Thereof
CN110551065B (zh) 氘代Lucitanib化合物及其用途
EP0402232A1 (fr) Dérivés de pyridobenzoindole, leur préparation et les compositions qui les contiennent
CN116102557B (zh) 苯二氮卓类化合物及其制备方法和在医药上的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23910989

Country of ref document: EP

Kind code of ref document: A1